Literature DB >> 19541684

Trisomy 7 and 17 mark papillary renal cell tumours irrespectively of variation of the phenotype.

I Balint1, A Szponar, A Jauch, G Kovacs.   

Abstract

BACKGROUND: Papillary renal cell tumours (RCTs) have been described as a genetic entity. Recently, papillary RCTs have been divided into small (type 1) and large (type 2) cell tumours. Subsequent DNA analyses have resulted in controversial data regarding putative genetic changes marking type 1 and type 2 tumours. AIM: The aim of this study was to improve the original description that papillary RCT is a genetic entity regardless of the phenotypic variation.
METHODS: DNA from 163 papillary RCTs, including 82 multiplex tumours from eight hereditary cases, was analysed for copy number changes by chromosomal comparative genomic hybridisation (CGH) and/or for allelic changes at chromosomes 7 and 17 by microsatellite analysis. The results of the genetic analysis were compared with the cytological characteristics of the tumours.
RESULTS: The results showed alterations of chromosomes 7 and 17 at similar frequencies in papillary RCTs with characteristics ranging from small to large cell, nuclear grade 1 to 3, and 3 mm to 16 cm diameter.
CONCLUSION: Trisomies of chromosomes 7 and 17 are specific genetic alterations in papillary RCTs irrespective of their size, grade and cellular differentiation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19541684     DOI: 10.1136/jcp.2009.066423

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Expression of KRT7 and WT1 differentiates precursor lesions of Wilms' tumours from those of papillary renal cell tumours and mucinous tubular and spindle cell carcinomas.

Authors:  Adrianna Szponar; Gyula Kovacs
Journal:  Virchows Arch       Date:  2012-03-02       Impact factor: 4.064

2.  Sciellin is a marker for papillary renal cell tumours.

Authors:  Anetta Nagy; Daniel Banyai; David Semjen; Tamas Beothe; Gyula Kovacs
Journal:  Virchows Arch       Date:  2015-10-16       Impact factor: 4.064

Review 3.  Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Authors:  Theodore F Logan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

4.  Papillary renal cell carcinoma embedded in an oncocytoma: Case report of a rare combined tumour of the kidney.

Authors:  István Sejben; Zoltán Szabó; Nándor Lukács; Márta Loránd; Farkas Sükösd; Gábor Cserni
Journal:  Can Urol Assoc J       Date:  2013 Jul-Aug       Impact factor: 1.862

Review 5.  c-Met as a Target for Personalized Therapy.

Authors:  Ingrid Garajová; Elisa Giovannetti; Guido Biasco; Godefridus J Peters
Journal:  Transl Oncogenomics       Date:  2015-11-23

6.  Recalling Cohnheim's Theory: Papillary Renal Cell Tumor as a Model of Tumorigenesis from Impaired Embryonal Differentiation to Malignant Tumors in Adults.

Authors:  Daniel Banyai; Donat P Sarlos; Anetta Nagy; Gyula Kovacs
Journal:  Int J Biol Sci       Date:  2018-05-21       Impact factor: 6.580

Review 7.  Hepatocyte nuclear factor 1 beta: A perspective in cancer.

Authors:  Shubhra Chandra; Srilakshmi Srinivasan; Jyotsna Batra
Journal:  Cancer Med       Date:  2021-02-13       Impact factor: 4.452

Review 8.  Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms.

Authors:  Ning Yi Yap; Retnagowri Rajandram; Keng Lim Ng; Jayalakshmi Pailoor; Ahmad Fadzli; Glenda Carolyn Gobe
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

9.  Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients.

Authors:  Xiaolu Yin; Tianwei Zhang; Xinying Su; Yan Ji; Peng Ye; Haihua Fu; Shuqiong Fan; Yanying Shen; Paul R Gavine; Yi Gu
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

10.  Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome.

Authors:  Paari Murugan; Liwei Jia; Renzo G Dinatale; Melissa Assel; Nicole Benfante; Hikmat A Al-Ahmadie; Samson W Fine; Anuradha Gopalan; Judy Sarungbam; S Joseph Sirintrapun; A Ari Hakimi; Paul Russo; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter
Journal:  Mod Pathol       Date:  2021-12-23       Impact factor: 8.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.